

**Contact:**  
PRISM BioLab Co., Ltd.  
info@prismbiolab.com

26-1, Muraoka-Higashi 2-  
chome, Fujisawa,  
Kanagawa 251-8555  
<https://prismbiolab.com>



**PRISM**  
BioLab

---

# PRESS RELEASE

## Notice Regarding the Termination of the Collaboration & License Option Agreement with Servier

TOKYO, Japan, October 3, 2025: -- PRISM BioLab, Co. Ltd. ("PRISM") announce that today, PRISM and LES LABORATOIRES SERVIER ("SERVIER") have mutually agreed to terminate the "Collaboration & License Option Agreement" (hereinafter referred to as "the Agreement") that was executed on June 3, 2021.

Under the Agreement the parties conducted joint research (hereinafter referred to as "the Joint Research") aimed at identifying candidate compounds against a challenging undruggable drug target proposed by SERVIER. The parties successfully identified compounds capable of binding the target protein and by X-ray crystallography analysis obtained advanced insights into their three-dimensional structures and intermolecular interactions.

Based on these achievements, the parties engaged in discussions regarding the possibility of further collaboration. However, considering the changing business priorities, we have mutually agreed not to proceed to the next phase and to amicably conclude the project. Accordingly, the Agreement covering this project has been terminated. The results of the Joint Research may be published in academic journals.

There will be no financial transactions associated with the termination of the Agreement, and this matter will have no impact on our financial results for the fiscal year. We consider the data and know-how obtained through four years of Joint Research to be a significant achievement and will continue to pursue partnerships with pharmaceutical companies and other organizations.

Sincerely,  
PRISM BioLab Co., Ltd.